The Paradigm Shift in Pulmonary Embolism Management: Primary Results from STORM-PE
Acute pulmonary embolism (PE) remains the third leading cause of cardiovascular death worldwide. While therapeutic strategies for high-risk (massive) PE are well-established, the optimal management of intermediate-high risk (submassive) PE has long been a subject of clinical debate. These patients, characterized by hemodynamic stability but evidence of right ventricular (RV) strain and myocardial injury, face a significant risk of clinical deterioration. Historically, anticoagulation alone has been the standard of care, but concerns regarding its speed in relieving RV pressure overload have led to the exploration of advanced reperfusion therapies.
The STORM-PE trial (A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone Versus Anticoagulation Plus Mechanical Aspiration With the Indigo Aspiration System for the Treatment of Intermediate-High Risk Acute Pulmonary Embolism) represents a landmark achievement in this space. It is the first randomized controlled trial (RCT) to evaluate the efficacy and safety of computer-assisted vacuum thrombectomy (CAVT) against the standard of anticoagulation alone.
